Biotech "Tweets of the Week"
Bleak Week for Biotechs
(October 31 - November 4, 2016)
Headlines - $AVXS $CEMP $ENDP $GILD $INFI $MYL $PFE $PTN $TEVA $VRX #ASH16
In the News - $ACHN $AGN $BLUE $BMRN $JUNO $KITE $LLY $MRGN $ONCE $QURE $SRPT $TGTX $TRIL $XBI $IBB
Looking for past biotech highlights? Check out the Biotech Tweets of the Week archive.
It's baaack...Valeant returns to the headlines $VRX
Valeant selling off a bit on this news. // Valeant Ex-CEO, Ex-CFO said to be focus of criminal probe. (BBG, CNBC) $VRX pic.twitter.com/DLQPS0IT7P
— Jack Damn □ (@JackDamn) October 31, 2016
Valeant in talks to sell Salix to Takeda for $10 bln -- would take out a huge chunk of debt in one swipe. $VRX up 13% w/ @jonathanrockoff
— Dave Benoit (@DaveCBenoit) November 1, 2016
$VRX bought Salix for $14.5B, selling for $10B. Excellent deal...https://t.co/dMAEybr3vY
— Andy Biotech (@AndyBiotech) November 1, 2016
if xifaxan is sold, $VRX largest product will be generic wellbutrin, 3rd largest will be provenge, per Q2 sales....just let that sink in
— zach (@zbiotech) November 1, 2016
$VRX 32% up
— Bursatil Biotech (@BursatilBiotech) November 1, 2016
Valeant Gets Some Breathing Room https://t.co/agFILNnvSM
— Charley Grant (@CGrantWSJ) November 1, 2016
$VRX
— Tom Wrigley (@WrigleyTom) November 2, 2016
Valeant Is Exploring Sale of Eye-Surgery Equipment Business -- Sources -Dow Jones
$VRX fire sale will not end its woes. Only expose that they over payed for their assets
— avidresearch (@avidresearch) November 1, 2016
Once-heralded PI3K inhibitors fall from grace $NVGN $INFI $RHHBY
Roche licenses out PI3K pathway brain cancer med to Oz biotech https://t.co/928qYMGypW
— Ron Leuty (@rleuty_biotech) October 31, 2016
Re Genentech out licensing pan-PI3K, per #ASCO16 it has "classic PI3K AEs" eg GR3 myocard ischemia, stomatitis. Valued for x'ng BBB. $TGTX
— Michael Goodman (@mikegoodma) November 1, 2016
On the ropes, Infinity gets a deal for duvelisib, with $0 up front as PI3k flounders$INFI $VSTM https://t.co/jxUHPtSmLF
— John Carroll (@JohnCendpts) November 2, 2016
New alert for PI3K fans: $INFI sells duvelisib for zero up front https://t.co/qiSri390OW Obviously of no relevance to $TGTX followers
— Jacob Plieth (@JacobPlieth) November 2, 2016
I just checked...there are literally zero tweets containing "PI3K" and #ASH16
— Andrew G. (@BioDueDiligence) November 4, 2016
Pfizer pulls plug on PCSK9 product $PFE $AMGN $SNY $REGN
$PFE ends development of its PCSK9 Bococizumab, saying it's "not likely to provide value to patients, physicians, or shareholders."
— Kristen Hallam (@kristen_hallam) November 1, 2016
https://t.co/KybMpWriu8 "unanticipated attenuation of low-density lipoprotein cholesterol (LDL-C) lowering over time" $PFE $AMGN $REGN $SNY
— Alp Bugra Basat M.D. (@AlpBugraBasat) November 1, 2016
$AMGN Huge binary just got even bigger (Repatha CVOT)
— I.M.Opinion (@subset_member) November 1, 2016
$PFE: bococizumab discontinuation is "based on the profile of our drug, not on profiles of other drugs." Decision came after 52-week data.
— Jessica Merrill (@Jessicaemerrill) November 1, 2016
Pfizer stops developing a #cholesterol drug, so who is the big winner? https://t.co/AILfOhhF43 #pharma $PFE $AMGN $SNY $REGN $MDCO $ALNY
— pharmalot (@pharmalot) November 1, 2016
Audience grows weary of Gilead's refrain $GILD
$GILD Q3 #HCV franchise $3.33B vs consensus of $3.75B, driven by big misses in both Harvoni and Sovaldi, somewhat offset by Epclusa big beat
— Andy Biotech (@AndyBiotech) November 1, 2016
$GILD Milligan says after triple HCV regimen is approved there's no unmet need left, so will turn attention to fibrosis, etc. in pipeline.
— Mandy Jackson (@ScripMandy) November 1, 2016
@AndyBiotech $GILDilocks
— Damian Garde (@damiangarde) November 1, 2016
If not4 crazy US tax code, $GILD could buyback COLOSSAL amnt of $GILD stock, which would be as productive4 shareholders as any M&A.
— Roy Friedman (@DewDiligence) November 1, 2016
When $GILD CEO says M&A assets are either too early or overpriced, it makes me wonder how much lower he thinks prices are going to go.
— BioBounce.com (@BioBounce) November 1, 2016
$GILD was Great Once but is Now Awful and Depressing https://t.co/l1resbMcGp Sad...
— Adam Feuerstein (@adamfeuerstein) November 2, 2016
$AGN "No more accretive asset on our radar than our own stock."
— Wolfmetric (@Wolfmetric) November 2, 2016
Ask $GILD how that sentiment has gone so far.
$GILD upgraded to Outperform From Market Perform by BMO
— Bio Stocks™ (@BioStocks) November 2, 2016
AveXis is this week's "Next Sarepta" with SMA drug update $AVXS
$AVXS might be able to get gene therapy approved based on current ph1 study, says FDA in mtg minutes included in co’s press release. wow!
— Adam Feuerstein (@adamfeuerstein) November 1, 2016
$IONS minus 10% in AH on this $AVXS reg update?https://t.co/qNI1bk65Wx
— Dirk Haussecker (@RNAiAnalyst) November 1, 2016
Good luck $AVXS, didn't want to wait til nusi approval?
AveXis shares soar after it outlines FDA’s support for a looming pivotal study on SMA$AVXS +25%https://t.co/Qvl3jbrBdR
— John Carroll (@JohnCendpts) November 1, 2016
$AVXS mentions $BIIB EAP. Says KOLs aren't concerned about ability to enroll. $IONS
— Jake King (@FajaJake) November 1, 2016
Comments on $AVXS ph3 announcement vs $IONS and $BIIB - https://t.co/f1pWINBCTw
— Clark H (@Clarksterh) November 1, 2016
Love AVXS with their "phase 1 gene therapy" has nearly half the MC of IONS, despite IONS having like $600M cash, partners & 39 more drugs
— WhiteCoatMafia (@WhiteCoatMafia) November 2, 2016
Palatin claims victory in female sexual dysfunction trials $PTN
$PTN Palatin female sexual desire drug succeeds in late stage trials https://t.co/qUZW4SEfSX +65% AH
— Antonio Costa (@ACInvestorBlog) November 1, 2016
$ptn also decides to switch endpoints around post factum making whichever one did not fail primary, "based on discussions with Fda", hokay
— Julia Skripka-Serry (@JuliaSkripkaSer) November 1, 2016
$PTN..$.76 AH..met their own endpts. Data is ok. Interested to see how it trades w/all the free warrants available. https://t.co/ndm4QdqYDL
— Sheff (@SheffStation) November 1, 2016
Folks, if you want to daytrade $PTN bc it's penny stock, go for it. Enjoy. But pls, don't tweet @ me like you think drug works. It doesn't.
— Adam Feuerstein (@adamfeuerstein) November 1, 2016
That was fast: $PTN Said to Explore Potential Sale, Reuters Says
— Sasha Damouni Ellis (@SashaDamouni) November 2, 2016
Cempra sinks on liver safety concerns ahead of FDA meeting $CEMP
MS $CEMP Fairly Valued Ahead of Briefing Docs ($18, 60% chance of neutral panel docs) with 100% Upside ($35) or 60% Downside ($7) Possible
— Asclepia Capital (@asclepiacap) November 1, 2016
$CEMP -- FDA: "We conclude that these findings comprise a genuine liver injury signal. " pic.twitter.com/4iz1T8zcbC
— Andy Biotech (@AndyBiotech) November 2, 2016
$CEMP..$13.60 in pre-mkt off briefing documents this a.m. More trouble than just CMC issues w/ liver toxicity emerging. https://t.co/HtZFXjlW9C
— Sheff (@SheffStation) November 2, 2016
Exited $CEMP (at a large loss) early in the PM;fortunately was able to get out early&grateful for BioTwitter-Not a fan of this dev. at all.
— Jason (@JasonHolman5) November 2, 2016
$cemp management trust gone with not disclosing information in regards to manufacturing issues plus undermining hepatotoxicity
— Pharm. D (@Pharmdca) November 2, 2016
@adamfeuerstein Thanks but all respect goes to @JohnTuckerPhD for a near flawless read of the soli situation, provided for free over twitter
— Brian Skorney (@BrianSkorney) November 2, 2016
$CEMP Took a small position in Cempra and let the dice roll. 2000 shares @ $7.30. Good luck to all.
— YipMan (@donaldyip) November 3, 2016
I foresee the word “armamentarium” being raised at adcomm tomorrow. Granted, that’s usually a good bet. It’ll battle with “hepatotoxicity.”
— Jessica Adams (@RxRegA) November 4, 2016
Generic drug's turn to enter the pricing spotlight $TEVA $MYL $ENDP
SCOOP: Massive probe into price-fixing by generic drug companies. Dozens under investigation. Charges by end of year https://t.co/vQ8pGYlUAP
— Drew Armstrong (@ArmstrongDrew) November 3, 2016
$MYL $TEVA *MYLAN, TEVA, ACTAVIS, LANNETT, IMPAX HAVE DISCLOSED SUBPOEANAS. *COVIS, SUN, MAYNE, TARO, ENDO'S PAR HAVE ALSO DISCLOSED PROBE
— Zeb (@zebamy) November 3, 2016
$LCI -25%$ENDP -19%$IPXL -15%$TEVA -7%$MYL -5%https://t.co/a1u297ICTh
— Andy Biotech (@AndyBiotech) November 3, 2016
Digoxin and Doxycycline are two key drugs in focus in this probe pic.twitter.com/6a7h6hBAMQ
The generic drug industry "isn’t going out of business, best that we can tell"
— Sasha Damouni Ellis (@SashaDamouni) November 3, 2016
Raymond James analyst says in note $MYL, $TEVA, $ENDP, $IPXL
New feature: Twitter "Moment" on #ASH16 Abstracts
As seen on the stream
165 HC calls this week:
— Brad Loncar (@bradloncar) October 30, 2016
M: $CAH
T: $GILD $INCY $PFE
W: $ALKS $AGN $ALNY
T: $TSRO #ASH16
F: $PETX $REGN
Full list: https://t.co/q0awPFyMDr
Biotech Movers 10/31 $ATOS $MBRX $OPHT $OPXA
— BioPharmCatalyst (@crusadernz) October 31, 2016
BPC Pipeline Updates $ACAD $ARIA $CAPR $CLBS $CLRB $MATN $OMER $SBPH https://t.co/fzImZKsU4Z
actually the list of #biotechs flat to down over the last three years is quite long including $GILD $IONS $AMAG $ACAD $NKTR to name a few
— Dan Rosenblum (@sharkbiotech) October 31, 2016
$NVS LEE011 (ribociclib) granted FDA Priority Review for first-line treatment of HR+/HER2- advanced breast cancer https://t.co/yX6EqJeJ9W
— Odi (@odibro) November 1, 2016
$PSTI Pluristem’s Pivotal Phase III Critical Limb Ischemia #CLI Trial Approved by UK Regulatory Agency https://t.co/dJpoKrwHt0
— Joe (@GantosJ) November 1, 2016
Biotech $IBB $XBI showing some relative strength (so far...) for the first time in like ages... aka a month. $LABU add.
— Jean Fonteneau (@JFinDallas) November 1, 2016
The latest pruning for Shire https://t.co/n7Q7TZB9vP $SHPG
— Arsalan Arif (@AKAarsalan) November 1, 2016
$PRQR now down 20% from PRIOR to NPD results at NACFC$PTI down 50%
— Jake King (@FajaJake) November 1, 2016
@Pharmdca yeah. That one is cash biz too it shouldn't matter long term.
— Adam Singer (@AdamSinger) November 1, 2016
$PFE will have 6 IO triplets in clinic in 2018! Hard to do all that without owning all assets in-house, hence IO target redundancy to date
— Michael Gladstone (@MikeNGladstone) November 1, 2016
JUST IN: $LLY shares fall after @SenSanders tweets about the pricing of one of the company's insulin drugs. pic.twitter.com/uJbAGqwt3v
— CNBC Now (@CNBCnow) November 1, 2016
Happy to make over 10% on $SGNL while other bios tanked. Like miRagen LT, but my thesis was achieved. Will develop cash redeployment plan
— Daniel Ward (@danwardbio) November 1, 2016
FDA Grapples with Hundreds of Vacancies - https://t.co/r2E7smOdm2
— StrengthenFDA (@StrengthenFDA) November 1, 2016
@odibro $AGN IMHO -better things to do with 10 BILLION Then what you just did -disappointed
— dough (@tgtxdough) November 2, 2016
.@brentlsaunders how come you're not tweeting your guidance cut? #boldforlife
— NathanAaron (@NathanAhron) November 2, 2016
$agn w/ div & greater share buyback. Oh btw, EPS miss, rev miss & cut guidance. Great spin on that PR.
— Joe (@Drchik23) November 2, 2016
Do listen to latest @TargetsPodcast on PARP inhibitors, biomarkers & novel immunotherapy combinations https://t.co/Q8FgbZz2G6 #ImmunoOnc
— Pieter Droppert (@3NT) November 2, 2016
This really is just a lackluster earnings season for pharma. Like, with the election, they all just said, "Why bother?"
— Matthew Herper (@matthewherper) November 2, 2016
Red flag #1 is ceo telling you stock is undervalued.
— NathanAaron (@NathanAhron) November 2, 2016
$ALKS terminates development of Alzheimer's agitation treatment
— Shane Blackmon (@shaneblackmon) November 2, 2016
They announced the offering late yesterday and they are now withdrawing it? $RDHL
— Juan P. Serrate, DVM (@JPZaragoza1) November 2, 2016
Just unbelievable selling in the small and micro cap biotech names. Even those that are cash rich. Entered a bit early on some, but adding.
— Undervaluedstxs (@undervaluedstxs) November 2, 2016
@Mykalt45 I am :>}
— John (@JohnTuckerPhD) November 2, 2016
@johntuckerphd Fantastic! Get good data and a partner to push through the clinic. Time is ticking! I’ve got a few ideas for our tech!
— Michael Torres, PhD (@Mykalt45) November 2, 2016
So...just signed a non-disclosure agreement, no coverage/tweets of the PRV conf., but yea, needless to say, some seriously frank talk
— Zach Brennan (@ZacharyBrennan) November 2, 2016
@JacobPlieth crispr studies are done in law firms these days
— mets17 (@adar170) November 2, 2016
$MRK The BACE1 inhibitor verubecestat MK-8931 reduces CNS β-amyloid in animal models & Alzheimer's disease patientshttps://t.co/CuhM1Odhg1
— Dan Marks (@Festivus159) November 2, 2016
@AdamSinger @23aloha I think we all need to go on vacation until after the election.
— Brad Loncar (@bradloncar) November 2, 2016
$alny have learned of additional death of a revusiran patient, death imbalance statistically significant
— Douglas Allan (@Dougallan1) November 2, 2016
@biologypartners @MaverickNY For sure, Bio negative sentiment is staggering
— Dan Smithey (@dan_smithey) November 2, 2016
And companies with two years of cash on the balance sheet trading at 52 week lows are selling shares through their ATM's why again?
— David Sable (@dbsable) November 3, 2016
It's been a very long wait for Roche to move $HALO SC products to the US. Rituximab BLA filed/accepted by FDA. https://t.co/29eO3merb8
— Brad Loncar (@bradloncar) November 3, 2016
$BMRN SEC subpoena related to former drisapersen program.
— Zeb (@zebamy) November 3, 2016
lol.
Does DTC advertising for advanced cancer Rx really increase sales? Someone reads this in the Chronicle & convinces their oncologist to Rx? pic.twitter.com/WriUe5t4eE
— Ethan Weiss (@ethanjweiss) November 3, 2016
$tril dec abstract importance increased.. solid tumor intratumoral trial going right into tumors... combos with rituximab 1b will be imp
— Boaty McBoatface (@srqstockpicker) November 3, 2016
@23aloha historically, it's the other way round... there's always a dumpalooza of some sort
— Sally Church (@MaverickNY) November 3, 2016
Discussion of social media's impact on rare diseases: patient advocacy networks help pharma work w/FDA 2 identify clinical endpts #NYNJCEO
— Pearl Freier (@PearlF) November 3, 2016
Sad week when I have to count my victories as simply staying away from certain companies always on the BioTwit screen ( $TRIL $BLUE )
— Jason (@JasonHolman5) November 3, 2016
$XBI is still $10 over its 52 week low. There have been at least 10 major blowups in the sector since then...
— Biotech, Beats & BBQ (@BiotechBbqBeats) November 3, 2016
$SRPT -- Wow!!! FDA just released tons of email communications and meeting minutes during eteplirsen review https://t.co/K7N4JF7opw pic.twitter.com/n6LCvlkzL1
— Andy Biotech (@AndyBiotech) November 4, 2016
'The sky is literally falling' - Health Care Investor Sentiment Sinks to End-Time Lows https://t.co/0qQtA0cVFQ
— Adam Feuerstein (@adamfeuerstein) November 4, 2016
Your Fri. morning pick-me-up
There is NO WAY that the few positive stories on biopharma (science, Rx approvals) counterbalances the negative @jonathanrockoff @DShaywitz https://t.co/uXynDdrWdU
— John LaMattina (@John_LaMattina) November 4, 2016
Jenkins on eteplirsen: Good people coming to diff conclusions. Ok to disagree. You don’t have to be disagreeable when you disagree #BPC2
— Laura Helbling (@Laura_H) November 4, 2016
FDA spox explains to me how a PRV can be revoked. Attn: @matthewherper @ZacharyBrennan pic.twitter.com/cNFZX1Kecg
— Adam Feuerstein (@adamfeuerstein) November 4, 2016
$ALXN 10-Q delay more significant than conference cancellation according to Leerink, since only investor relations were attending conf
— Vk (@biotechinvstr) November 4, 2016
NEW: My very frank talk to drug industry on innovation & drug costs last night.https://t.co/LMGNWmEJYT
— Andy Slavitt (@ASlavitt) November 4, 2016
A tip of the hat
Congrats and well done at the opening bell @bradloncar @LoncarFunds @NASDAQ @CancerResearch #immunotherapy pic.twitter.com/axW6pm3gc0
— Perth Tolle (@Perth_Tolle) October 31, 2016
Patent conversion deadlines met & success = PCT filing receipts
— Paul D. Rennert (@PDRennert) October 31, 2016
And now we can talk about it...https://t.co/weB85ASpCW
New digs pic.twitter.com/EwKOwkZ6wi
— John (@JohnTuckerPhD) November 1, 2016
We leave you with this
BioTwitter shot! @bradloncar @NASDAQ @dbsable @SheffStation @princetongb @biotechbaumer @AF_biotech @chasingthealpha @MaxJacobsEdison+others pic.twitter.com/vSSTUrzSlr
— Amit Jolly (@amitkjolly) October 31, 2016
You guys, I finally booked a hotel room for #JPM17. Whew. Also, how is it already November?
— Lisa Jarvis (@lisamjarvis) November 1, 2016
